NZ608177A - Long acting compositions - Google Patents
Long acting compositionsInfo
- Publication number
- NZ608177A NZ608177A NZ60817712A NZ60817712A NZ608177A NZ 608177 A NZ608177 A NZ 608177A NZ 60817712 A NZ60817712 A NZ 60817712A NZ 60817712 A NZ60817712 A NZ 60817712A NZ 608177 A NZ608177 A NZ 608177A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- oil
- cyclic amide
- present
- amide solvent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 148
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims abstract description 66
- 239000002904 solvent Substances 0.000 claims abstract description 43
- 239000004359 castor oil Substances 0.000 claims abstract description 30
- 235000019438 castor oil Nutrition 0.000 claims abstract description 30
- 150000003950 cyclic amides Chemical class 0.000 claims abstract description 30
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 30
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 229960004816 moxidectin Drugs 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 25
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000005660 Abamectin Substances 0.000 claims abstract description 11
- 239000008365 aqueous carrier Substances 0.000 claims abstract description 10
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims abstract description 7
- 229960003997 doramectin Drugs 0.000 claims abstract description 7
- 208000030852 Parasitic disease Diseases 0.000 claims abstract description 6
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 claims abstract description 5
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims abstract description 4
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims abstract description 4
- 229960002418 ivermectin Drugs 0.000 claims abstract description 4
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims abstract description 3
- 229950008167 abamectin Drugs 0.000 claims abstract description 3
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 claims abstract description 3
- 229960002245 selamectin Drugs 0.000 claims abstract description 3
- 229940000188 cydectin Drugs 0.000 claims description 41
- -1 lactone compound Chemical class 0.000 claims description 16
- 239000003963 antioxidant agent Substances 0.000 claims description 15
- 230000003078 antioxidant effect Effects 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 10
- 235000019198 oils Nutrition 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 7
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 7
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 7
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 6
- 235000010469 Glycine max Nutrition 0.000 claims description 6
- 239000007972 injectable composition Substances 0.000 claims description 6
- 235000012343 cottonseed oil Nutrition 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- 239000002385 cottonseed oil Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008159 sesame oil Substances 0.000 claims description 3
- 235000011803 sesame oil Nutrition 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 2
- 235000019483 Peanut oil Nutrition 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000000828 canola oil Substances 0.000 claims description 2
- 235000019519 canola oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000002540 palm oil Substances 0.000 claims description 2
- 239000000312 peanut oil Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 239000001384 succinic acid Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 1
- 239000012867 bioactive agent Substances 0.000 abstract description 21
- 230000000507 anthelmentic effect Effects 0.000 abstract description 16
- 150000002596 lactones Chemical class 0.000 abstract description 7
- 239000003124 biologic agent Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 31
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 238000003197 gene knockdown Methods 0.000 description 15
- 239000013543 active substance Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 10
- 235000013601 eggs Nutrition 0.000 description 9
- 230000000975 bioactive effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 244000045947 parasite Species 0.000 description 7
- 238000003307 slaughter Methods 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 241001494479 Pecora Species 0.000 description 5
- 229940124339 anthelmintic agent Drugs 0.000 description 5
- 239000000921 anthelmintic agent Substances 0.000 description 5
- 229960002903 benzyl benzoate Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 4
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 4
- 229940093471 ethyl oleate Drugs 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 230000001418 larval effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000893172 Chabertia Species 0.000 description 3
- 241001126268 Cooperia Species 0.000 description 3
- 241000243974 Haemonchus contortus Species 0.000 description 3
- 241000243797 Trichostrongylus Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 241000202814 Cochliomyia hominivorax Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000002163 Mesapamea fractilinea Species 0.000 description 2
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 2
- 241000510960 Oesophagostomum Species 0.000 description 2
- 241000243795 Ostertagia Species 0.000 description 2
- 210000003165 abomasum Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 244000079386 endoparasite Species 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 150000003278 haem Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000000590 parasiticidal effect Effects 0.000 description 2
- 239000002297 parasiticide Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004348 Glyceryl diacetate Substances 0.000 description 1
- 241000243976 Haemonchus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000006123 Myiasis Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241001137882 Nematodirus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000244174 Strongyloides Species 0.000 description 1
- 241000191771 Teladorsagia circumcincta Species 0.000 description 1
- 241000122945 Trichostrongylus axei Species 0.000 description 1
- 241000243796 Trichostrongylus colubriformis Species 0.000 description 1
- 241001489151 Trichuris Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000005676 cyclic carbonates Chemical class 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 1
- 229960002346 eprinomectin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 235000019443 glyceryl diacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical group 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
- CLAIM 1. A composition for the treatment of an animal in need thereof wherein the composition includes a therapeutically effective amount of at least one macrocyclic lactone compound characterised in that the composition includes a non-aqueous carrier and a solvent system including castor oil and at least one cyclic amide solvent.
- 2. The composition as claimed in claim 1 wherein the cyclic amide solvent is a pyrrolidone.
- 3. The composition as claimed in either claim 1 or claim 2 wherein the cyclic amide solvent in the composition is N-Methylpyrrolidone (NMP).
- 4. The composition as claimed in any of the above claims wherein the cyclic amide solvent is present in the composition in an amount of between 1- 50% w/v.
- 5. The composition as claimed in any one of the above claims wherein the castor oil is present in the composition in an amount between 1-20% w/v.
- 6. The composition as claimed in any one of the above claims wherein the composition is an injectable composition.
- 7. The composition as claimed in any one of the above claims wherein the macrocyclic lactone compound is selected from the group consisting of avermectin, moxidectin, milbemycin, ivermectin, abamectin, doramectin, epinomectin and selamectin. 9. The composition as claimed in any one of claims 7 to 8 wherein the macrocyclic lactone compound is moxidectin. 10. The composition as claimed in any one of the above claims wherein the macrocyclic lactone compound is present in the composition between 0.005 to 15% w/v. 11. The composition as claimed in any one of the above claims wherein the macrocyclic lactone compound is present in the composition between 0.005 to 5% w/v. 12. The composition as claimed in any of the above claims wherein the non- aqueous carrier includes an oil selected from the group consisting of canola oil, corn oil, cottonseed oil, olive oil, peanut oil, sesame oil, soyabean oil, safflower oil, coconut oil, sunflower oil, palm oil, monoglyceride, diglyceride and triglyceride medium chain succinic acid triglyceride. 13. The composition as claimed in any of the above claims wherein the cyclic amide solvent is present in the composition at approximately 15% w/v. 14. The composition as claimed in any of the above claims wherein the castor oil is present in the composition at approximately 7% w/v. 15. The composition as claimed in any of the above claims wherein the composition includes an antioxidant. 16. The composition as claimed in claim 15 wherein the antioxidant is butylated hydroxytoluene (BHT). 17. The composition as claimed in either claim 15 or claim 16 wherein the antioxidant is present in the composition between 0.001 to 10% w/v. 18. The composition as claimed in any one of claims 15 to 17 wherein the antioxidant is present in the composition at approximately 0.05 % w/v. 19. A method of treating a non-human animal in need thereof with a composition as claimed in any one of claims 1 to 18, including the step of delivering the composition to the animal to provide a long acting protection against or treatment for a given condition or disease. 20. The method as claimed in claim 19 wherein the condition is a parasitic infection in or on a non-human animal. 21. A use of the composition as claimed in any one of claims 1 to 18 for the manufacture of a medicament for the long acting treatment or prevention against a parasitic infection in or on a non-human animal. 22. A method of preparing a composition including a macrocyclic lactone compound characterised by the step of adding castor oil and at least one cyclic amide solvent to the macrocyclic lactone compound. 22. The method as claimed in claim 21 including the steps of: a) adding the cyclic amide solvent to a manufacturing container; b) adding the macrocyclic lactone compound to the cyclic amide solvent; c) adding castor oil to the agent/cyclic amide mixture; and d) adding a non-aqueous carrier up to volume. 23. A composition as herein described with reference to the accompanying figures and examples in the Best Mode Section, but excluding the composition referred to in the figures and examples as Cydectin. 24. A method of treating a non-human animal in need thereof with the composition as claimed in claim 23 with reference to the accompanying figures and examples in the specification. 25. A method of manufacturing a composition as herein described with reference to the accompanying figures and examples in the Best Mode Section, but excluding the composition referred to in the figures and examples as Cydectin. Bayer New Zealand Limited by their authorised agents JAMES & WELLS INTELLECTUAL PROPERTY
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ60817712A NZ608177A (en) | 2012-03-13 | 2012-03-13 | Long acting compositions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ60817712A NZ608177A (en) | 2012-03-13 | 2012-03-13 | Long acting compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ608177A true NZ608177A (en) | 2014-10-31 |
Family
ID=51796531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ60817712A NZ608177A (en) | 2012-03-13 | 2012-03-13 | Long acting compositions |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ608177A (en) |
-
2012
- 2012-03-13 NZ NZ60817712A patent/NZ608177A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6653288B1 (en) | Injectable anthelmintic compositions and methods for using same | |
ES2233566T3 (en) | PROLONGED RELEASE COMPOSITIONS FOR THE PARENTERAL ADMINSITRATION OF MACROLITES. | |
JPH05246893A (en) | Long-acting antiparasitic injectable formulation containing hydrogenated castor oil | |
AU2006322120B2 (en) | Benzimidazole non-aqueous compositions | |
US20060142216A1 (en) | Parasiticidal composition | |
AU2010233409B2 (en) | High dosage doramectin formulation | |
AU2013201479B2 (en) | Long Acting Compositions | |
NZ548938A (en) | Topical macrocyclic lactone formulation | |
NZ608177B2 (en) | Long acting compositions | |
NZ608177A (en) | Long acting compositions | |
EA002628B1 (en) | Water dispersed ivermectin dosage form for curing ecto- endoparasitic diseases | |
MX2014008172A (en) | Pharmaceutical composition comprising isometamidium chloride in solution for the treatment of trypanosomiasis in animals. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2018 BY BAYER NEW ZEALAND LIMITED Effective date: 20170213 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2019 BY JAMES + WELLS Effective date: 20180222 |
|
ERR | Error or correction |
Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 13 MAR 2013; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2013; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 05 SEP 2014; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2014; STATUS: OVERWRITTEN; KIND CODE: PUBLICATION DATE: 31 OCT 2014; TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2014; STATUS: GRANTED; KIND CODE: B2 PUBLICATION DATE: 24 APR 2015; TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 11 JUN 2018; STATUS: ACCEPTED; KIND CODE: Effective date: 20180629 Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 13 MAR 2013; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2013; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 05 SEP 2014; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2014; STATUS: OVERWRITTEN; KIND CODE: PUBLICATION DATE: 31 OCT 2014; TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2014; STATUS: SUPERSEDED; KIND CODE: B2 PUBLICATION DATE: 24 APR 2015; TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 11 JUN 2018; STATUS: ACCEPTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 03 JUL 2018; STATUS Effective date: 20180703 Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 13 MAR 2013; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2013; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 05 SEP 2014; STATUS: REJECTED; KIND CODE: TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2014; STATUS: ACCEPTED; KIND CODE: PUBLICATION DATE: 31 OCT 2014; TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 24 SEP 2014; STATUS: SUPERSEDED; KIND CODE: B2 PUBLICATION DATE: 24 APR 2015; TITLE: LONG ACTING COMPOSITIONS; FILING DATE: 03 JUL 2018; STATUS: GRANTED; KIND CODE: C2 Effective date: 20180704 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2020 BY BAYER NEW ZEALAND LIMITED Effective date: 20181213 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2021 BY BAYER NEW ZEALAND LIMITED Effective date: 20191216 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2022 BY JAMES + WELLS Effective date: 20210211 |
|
ASS | Change of ownership |
Owner name: ELANCO NEW ZEALAND SIMPSON GRIERSON, NZ Effective date: 20210707 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2023 BY THOMSON REUTERS Effective date: 20220302 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2024 BY THOMSON REUTERS Effective date: 20230201 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAR 2025 BY THOMSON REUTERS Effective date: 20240201 |